(Q50887636)

24 March 2018

title

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. (English)

1 reference

24 March 2018

low-grade serous carcinoma

1 reference

1 reference

0 references

7

Isabelle Ray-Coquard

1 reference

24 March 2018

author name string

Jacek P Grabowski

1

1 reference

24 March 2018

Philipp Harter

2

1 reference

24 March 2018

Florian Heitz

3

1 reference

24 March 2018

Eric Pujade-Lauraine

4

1 reference

24 March 2018

Alexander Reuss

5

1 reference

24 March 2018

Gunnar Kristensen

6

1 reference

24 March 2018

Julia Heitz

8

1 reference

24 March 2018

Alexander Traut

9

1 reference

24 March 2018

Jacobus Pfisterer

10

1 reference

24 March 2018

Andreas du Bois

11

1 reference

24 March 2018

language of work or name

English

0 references

publication date

22 January 2016

1 reference

24 March 2018

published in

Gynecologic Oncology

1 reference

24 March 2018

volume

140

1 reference

24 March 2018

issue

3

1 reference

24 March 2018

page(s)

457-462

1 reference

24 March 2018

Grading ovarian serous carcinoma using a two-tier system

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Diverse tumorigenic pathways in ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Low-grade serous ovarian cancer: a unique disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

[The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Pattern of Care and Reality in Germany 2001]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Recurrent micropapillary serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Epidemiology of low-grade serous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Non-enrolment of ovarian cancer patients in clinical trials: reasons and background

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Specialized pathology review in patients with ovarian cancer: results from a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

[Specialized histopathological second opinion of advanced ovarian cancer. Experiences with collectives from prospective randomized phase III studies].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Low-grade serous carcinoma: new concepts and emerging therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.01.022

10.1016/J.YGYNO.2016.01.022

7 January 2021

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018